Amit Jain, MD

Articles by Amit Jain, MD

Dr. Jain on the Benefit of CDK7 Inhibitors in HR+ Breast Cancers

ByAmit Jain, MD

October 18th 2022

Amit Jain, MD, discusses the benefit of CDK7 inhibitors in hormone receptor–positive breast cancers.

Dr. Jain on Potential Biomarkers in HR-Positive, HER2-Negative Breast Cancer

ByAmit Jain, MD

July 13th 2022

Amit Jain, MD, discusses the potential role of emerging biomarkers in selecting treatment with CDK7 inhibitors in patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Amit Jain, MD

Articles by Amit Jain, MD

Dr. Jain on the Benefit of CDK7 Inhibitors in HR+ Breast Cancers

Dr. Jain on Potential Biomarkers in HR-Positive, HER2-Negative Breast Cancer

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts

The OncFive: Top Oncology Articles for the Week of 1/25

FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma

Oncology Fellows Presents a New Drug Cheat Sheet for Fellows